Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histrelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.76 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | APLNR | P35414 | 4/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | MC5R | P33032 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | MC1R | Q01726 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histrelin SCHEMBL5327685 | 1.00 | ABCC2 (0.78) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL29372688 | 1.00 | ABCC2 (0.78) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL17881 | 0.99 | GNRHR (0.77) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL29405757 | 0.99 | GNRHR (0.77) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL7619565 | 0.99 | GNRHR (0.77) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Histrelin SCHEMBL84261 | 0.99 | GNRHR (0.76) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL570851 | 0.94 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.94 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL177978 | 0.94 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.94 | ABCC2 (0.87) | ABCC2GNRHRPTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7530 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| US-20250262270-A1 | COMPOSITIONS AND METHODS FOR TREATING PRECOCIOUS PUBERTY | ENDO OPERATIONS LIMITED (IE) | 2025-08-21 | — | — | US | claimed |
| US-20250213523-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-07-03 | — | — | US | claimed |
| EP-4566675-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| US-20250177358-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2025-06-05 | — | — | US | claimed |
| US-12268670-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | AURIGENE ONCOLOGY LIMITED (IN) | 2025-04-08 | — | — | US | claimed |
| CN-119546293-A | Combination of HDAC inhibitors and statins for the treatment of pancreatic cancer | 国家癌症研究所IRCCS-G·帕斯卡莱基金会 | 2025-02-28 | — | — | CN | claimed |
| US-20250051384-A1 | NEUTRAL GLYCOSYLATED AMIDES AND DIANIONIC GLUCURONIDATED ACIDS AS STABILIZERS FOR BIOLOGICAL MOLECULES | EXTREMOCHEM, LDA. (PT) | 2025-02-13 | — | — | US | claimed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | claimed |
| WO-2007109178-A2 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| EP-1773293-A2 | COMPOSITIONS AND METHODS FOR TREATING CENTRAL PRECOCIOUS PUBERTY | Valera Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006107903-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-10-12 | — | — | WO | claimed |
| WO-2006009801-A2 | COMPOSITIONS AND METHODS FOR TREATING CENTRAL PRECOCIOUS PUBERTY | VALERA PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060019903-A1 | Compositions and methods for treating precocious puberty | COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION | 2006-01-26 | — | — | US | claimed |
| US-6096764-A | ELIMINATING THE DETRIMENTAL SIDE-EFFECTS ASSOCIATED WITH THE CONTINUOUS AND CHRONIC USE OF GONDATROPIN-RELEASING HORMONE FACTOR OR AGONIST BY ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| WO-1999008677-A1 | METHODS FOR INHIBITING DETRIMENTAL SIDE-EFFECTS DUE TO GnRH OR GnRH AGONIST ADMINISTRATION | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0897721-A2 | Benzo(b)thiophene derivatives for inhibiting detrimental side-effects due to GnRH or GnRH agonist administration | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | claimed |